A Phase I/II Dose-escalating Study of the Safety, Tolerability and Efficacy of KIO-301 Administered Intravitreally to Patients With Retinitis Pigmentosa and Choroideremia (ABACUS)
Condition(s):Retinitis Pigmentosa; ChoroideremiaLast Updated:March 15, 2024Recruiting